Today! #ESMOImmuno22

Presenting our UK-Switzerland collaboration in #SCLC at #ESMOImmuno22

End of year wrap up of immunotherapy progress in GI cancer at #ESMOImmuno22 congress today esmo.org/meeting-calend…. Chaired by Barts Health oncologist Marco Gerlinger and Lorenza Rimassa, fantastic speakers discussed practice changing data and future directions in HCC, CRC, OG

Walking to the conference venue, I love to see the Alpes! ⛷️ #ESMOImmuno22

Happy to run into interesting work done at Hospital del Mar

#ESMOImmuno22 #LCSM

Congrats Laura Masfarré Pintó

#ESMOImmuno22 #Geneva Pleasure to present LIVE #biomarker Team #Science data #ORIEN
⁦Moffitt Cancer Center⁩ The James⁩ ⁦⁦UVA Cancer Center⁩ UI Holden Comprehensive Cancer Center ⁦GW Cancer Center⁩ UNM Comprehensive Cancer Center IU Health Markey Cancer Center RutgersCancerInstNJ USC Norris Comprehensive Cancer Center OU Health Stephenson Cancer Center Roswell Park IU Health

#ESMOImmuno22 Fabrice Barlesi presenting PIONeeR trial - a model to investigate BMK of response to CPI in NSCLC ESMO - Eur. Oncology John Haanen Benjamin Besse d.planchard

Great to be part of #ESMOImmuno22 in Geneva. So proud! ESTENSIS - The Conference Buddies POSTERWALK

Let’s start #ESMOImmuno22 🏹 in #Geneva #immunotherapy #IO ⁦ESMO - Eur. Oncology⁩ ⁦OncoAlert⁩

#ESMOImmuno22 :a great scientific program, bridging between research & clinical practice, experts sharing their work, unpublished data & insight on future developments in IO, inspiring YOC mentorships sessions & an opportunity to (re)connect with colleagues & friends. C u in 2023!

let the PD1 wars begin! #ESMOImmuno22 dostarlimab seems not only non-inferior, but trends for superiority vs pembro, with CT in NSCLC 1L. supported by trend increasing with hi PDL1. not only a metoo drug then... what is the 'perfect' anti-PD1?

Different PD-(L)1 inhibitors are often thought to have similar to identical clinical efficacy and safety. Do they?

First trial with a head to head comparison presented by Solange Peters at #ESMOImmuno22

Post B cell session photo with my amazing colleagues! #Bcells #TLS I was so thrilled to be part of this dynamic line up! Ziv Shulman Lab Mauri Lab UCL ESMO - Eur. Oncology #ESMOImmuno22

Excited to present at my first international conference! Many thanks to Allison Betof Warner, MD, PhD for her incredible mentorship, and Weill Cornell Internal Medicine Chief Residents for the support to make this possible! #ESMOImmuno22

Why we need new IO strategies in lung… #esmoimmuno22 Solange Peters ESMO - Eur. Oncology

🕵🏽‍♂️Exciting poster presentation at #ESMOImmuno22 ESMO - Eur. Oncology of our network meta-analysis on 1L treatments for advanced #Melanoma ➡️ special thanks to Francesco Spagnolo Matteo Lambertini, MD PhD Luca Arecco, MD Università di Genova Ospedale San Martino Genova

Adagrasib + pembrolizumab as first-line treatment for patients with NSCLC harboring a KRASG12C mut. Excellent response rates with manegeable toxicity. Very proud to participate in the KRYSTAL7 trial Fundación Jiménez Díaz UAM Autónoma Madrid ESMO - Eur. Oncology KRASKickers #ESMOImmuno22 OncoAlert #LCSM

#MatteoSimonelli discussing novel #immunotherapy approaches for patients with solid tumors at #ESMOImmuno22 ESMO - Eur. Oncology Humanitas University Humanitas Milano

GOING HOME! 😀🦊 Honored to work a scientist & travel to exchange knowledge in global effort to #FinishCancer ! Great meeting colleagues in #Napoli #Bridge2022 , #Terni & #Geneva #ESMOImmuno22 Learned so much! KLM/Delta to #Portland ! Chiles Research Institute Society for Immunotherapy of Cancer Paolo A. Ascierto @ubivac

#ESMOImmuno22

PERLA trial with Solange Peters's great presentation:

First study comparing two Anti-PD1 agents in NSCLC.

☑️Dostarlimab met primary endpoint.

💥Comparisons of drugs in the same group are very valuable in order to decrease drug prices.

OncoAlert ESMO - Eur. Oncology